Fig. 6From: Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart studyEffectiveness outcomes by change from baseline in MIDAS score: A) total population; B) dosing schedule subgroups; C) prior treatment failures subgroups. BL, baseline; MIDAS, Migraine Disability Assessment; Q, quarterly; M, monthly. aNumber of patients with available assessment at each time pointBack to article page